159 related articles for article (PubMed ID: 22978686)
1. Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
Shinohara A; Yoshiki Y; Masamoto Y; Hangaishi A; Nannya Y; Kurokawa M
Leuk Lymphoma; 2013 Apr; 54(4):794-8. PubMed ID: 22978686
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone prophylaxis: worth the cost?
Haeusler GM; Slavin MA
Leuk Lymphoma; 2013 Apr; 54(4):677-8. PubMed ID: 23035818
[No Abstract] [Full Text] [Related]
3. Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy.
Takahashi M; Takahashi K; Ogawa K; Takashima T; Asano Y; Kashiwagi S; Noda S; Onoda N; Ohira M; Nagayama K
Support Care Cancer; 2019 Aug; 27(8):2829-2836. PubMed ID: 30547304
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of moxifloxacin (Avelox) in prophylaxis of infection in patients with profound neutropenia].
Minenko SV; Dmitrieva NV; Sokolova EN; Zhukov NV; Ptushkin VV
Antibiot Khimioter; 2004; 49(3):26-31. PubMed ID: 15344394
[TBL] [Abstract][Full Text] [Related]
5. Treatment with fluorated quinolones of febrile neutropenia in patients with hematologic malignancies.
Nenova IS; Goranov SE; Mateva NG; Ananoshtev NH
Folia Med (Plovdiv); 2003; 45(1):13-9. PubMed ID: 12943062
[TBL] [Abstract][Full Text] [Related]
6. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
Chamilos G; Bamias A; Efstathiou E; Zorzou PM; Kastritis E; Kostis E; Papadimitriou C; Dimopoulos MA
Cancer; 2005 Jun; 103(12):2629-35. PubMed ID: 15856427
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.
Przybylski DJ; Reeves DJ
Support Care Cancer; 2017 Dec; 25(12):3715-3721. PubMed ID: 28660351
[TBL] [Abstract][Full Text] [Related]
8. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
[TBL] [Abstract][Full Text] [Related]
9. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
Sebban C; Dussart S; Fuhrmann C; Ghesquieres H; Rodrigues I; Geoffrois L; Devaux Y; Lancry L; Chvetzoff G; Bachelot T; Chelghoum M; Biron P
Support Care Cancer; 2008 Sep; 16(9):1017-23. PubMed ID: 18197434
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin prophylaxis in neutropenic patients.
von Baum H; Sigge A; Bommer M; Kern WV; Marre R; Döhner H; Kern P; Reuter S
J Antimicrob Chemother; 2006 Oct; 58(4):891-4. PubMed ID: 16880172
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
[TBL] [Abstract][Full Text] [Related]
12. Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance.
Ng ES; Liew Y; Earnest A; Koh LP; Lim SW; Hsu LY
Leuk Lymphoma; 2011 Jan; 52(1):131-3. PubMed ID: 20929324
[No Abstract] [Full Text] [Related]
13. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.
Rolston KV; Frisbee-Hume SE; Patel S; Manzullo EF; Benjamin RS
Support Care Cancer; 2010 Jan; 18(1):89-94. PubMed ID: 19387695
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.
Mayer K; Hahn-Ast C; Mückter S; Schmitz A; Krause S; Felder L; Bekeredjian-Ding I; Molitor E; Brossart P; von Lilienfeld-Toal M
Support Care Cancer; 2015 May; 23(5):1321-9. PubMed ID: 25617073
[TBL] [Abstract][Full Text] [Related]
15. Safe fluoroquinolones prophylaxis in blood cancer patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-Dehydrogenase deficiency.
Sanna M; Caocci G; Orrù F; Ledda A; Vacca A; Piras E; Fozza C; Deias P; Tidore G; Dore F; La Nasa G
J Clin Pharm Ther; 2017 Dec; 42(6):733-737. PubMed ID: 28597476
[TBL] [Abstract][Full Text] [Related]
16. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Deramo VA; Lai JC; Fastenberg DM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):721-5. PubMed ID: 16989762
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
Vehreschild JJ; Moritz G; Vehreschild MJ; Arenz D; Mahne M; Bredenfeld H; Chemnitz J; Klein F; Cremer B; Böll B; Kaul I; Wassmer G; Hallek M; Scheid C; Cornely OA
Int J Antimicrob Agents; 2012 Feb; 39(2):130-4. PubMed ID: 22169408
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
Gafter-Gvili A; Fraser A; Paul M; Leibovici L
Ann Intern Med; 2005 Jun; 142(12 Pt 1):979-95. PubMed ID: 15968013
[TBL] [Abstract][Full Text] [Related]
19. [Fluoroquinolones to prevent bacterial infection in children with chemotherapy induced neutropenia: is it reasonable?].
Dubos F; Delebarre M; Lagrée M
Arch Pediatr; 2013 Nov; 20 Suppl 3():S90-3. PubMed ID: 24360309
[TBL] [Abstract][Full Text] [Related]
20. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
